Clinical trial workflow platform OneStudyTeam, a Reify Health company, announced its partnership with Antidote Technologies, a digital patient engagement company, to provide an end-to-end clinical trial recruitment platform.
OneStudyTeam’s cloud-based software StudyTeam connects study sites and sponsors to assist in recruiting, prescreening and enrolling patients in clinical trials.
Antidote’s patient engagement platform connects sponsors and patients. It’s now integrated with StudyTeam’s Referral Partner Interface.
“Where OneStudyTeam provides visibility to measure and understand gaps in enrollment strategy, Antidote has mastered identifying those critical patients and matching them to the right trial,” Ralph Passarella, CEO of OneStudyTeam, said in a statement. “This collaboration spans the recruitment and enrollment continuum to drive diversity, equity, inclusion, and representation among trial candidates.”
THE LARGER TREND
The Boston-based OneStudyTeam is an initiative of Reify Health, which offers clinical trial and infrastructure support.
Antidote, based in the U.S. and U.K., was launched as TrialReach more than a decade ago, then rebranded to Antidote in 2016.
Reify garnered $220 million in Series D funding in April, boosting the company’s valuation to $4.8 billion.
That round came less than a year after the company raised $220 million in Series C funding. The company also brought in $30 million in Series B financing in 2020.
Source: Mobi Health News
